Funded project
IP-NFT
Matrix Bio

Matrix Bio

Cancer
Aging
Hyaluronic acid
VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rat to human.
Funding
$ 300,000
Initiated
31.3.2023
Approval
99.99% Voted Yes
Vera Gorbunova
Research Lead
Eleanor Davies
Project Manager
Anthony Schwartz, PhD
Project Lead
Greg Tombline, PhD
Scientist
AT A GLANCE

Stage
Early stage preclinical discovery

Area
Drug discovery

Status

Ongoing

Patent Status

Not filed yet

PROJECT LINKS

Background

Naked mole rats (NMR) are long-lived rodents with a lifespan of up to 40 years, compared to normal rats which live about three years. Unlike other rodents, NMR are found to be cancer resistant. Previous research by the Gorbunova lab has demonstrated cancer resistance in NMR is modulated by the abundance of high molecular weight hyaluronic acid (HMW-HA) in tissues. Additional research has demonstrated that transgenic mice expressing naked mole rat hyaluronan synthase gene (NHAS2) have less tumours, improved health, and live 10% longer than mice without the transgene. 

Aims, Hypothesis & Results

To increase HA in human patients and translate these findings into the clinic, this project will screen and develop small molecule inhibitors of hyaluronidases, the enzymes that break down hyaluronic acid. These compounds can be used for cancer treatment and are expected to increase human healthspan and lifespan.

Timeline

Program 1: HTS and med chem for new inhibitors

Phase 1: High Throughput Screening (HTS) – up to $100k

Phase 2: Medicinal Chemistry on hits – up $100k

Program 2: Validation of existing in vivo active inhibitor (EC50 ~ 20 µM)

Administration of hit compound to mouse models of cancer to test for curative and preventative effects - up to $100k

VitaDAO Board Evaluation Writeup

Vera Gorbunova is a world leader in the field of comparative biology with a focus on longevity and healthspan mechanisms. She proposes a unique approach with relatively little competition on the MoA and a straightforward road to NCE IP. There is strong published and supporting evidence for the target in mice. The mechanism for cancer prevention seems to be well established via CD44. There is already a screen hit with a potential asset in hand. This could be a first DeSci project, where the DAO is spinning out the company and that is a step forward for the community.

However, the hyaluronan role in cancer is somewhat controversial: on one hand, HMW-HA production is linked to cancer resistance, on the other hand, HMW-HA is involved in driving and maintaining malignant progression. The underlying hypothesis needs more PoC data to be further substantiated. It is unclear if the proposed intervention would work systemically to increase life/health span and reduce cancer in humans. The project is early and very high risk, but no insurmountable weaknesses.

Projects supported

Non Consectetur Necessitatibus

Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa

$293,00
raised
View Project

Dolorum Quia

Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex

$293,00
raised
View Project

Ex Temporibus Perferendis

Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda

$293,00
raised
View Project

Eum Harum Asperiores Id

Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin

$293,00
raised
View Project

Aperiam Et Quis Et

Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s

$293,00
raised
View Project

Culpa Possimus

Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod

$293,00
raised
View Project

Earum Est Dolorem

Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus

$293,00
raised
View Project

Voluptas Quam Sapiente

Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u

$293,00
raised
View Project

Nisi

Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l

$293,00
raised
View Project

Aut Accusantium Ut

Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita

$293,00
raised
View Project
Latest Project Updates
No items found.
31
March
2023
Project Initiated!

Discover more projects & initiatives

Humanity

Equity

Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

$ 50,000
raised
View Project

BE Therapeutics - Brain Tissue Replacement

Equity

The neocortex, the part that underlies our highest cognitive functions and self-identity, can be replaced by progressively replacing tissue areas over time without significant disruption in function or self-identity. This offers the possibility of age reversal for the neocortex through progressive tissue replacement.

$ 100,000
raised
View Project

ExcepGen Inc - RNA therapeutics for longevity

Equity

ExcepGen uses its RNAx platform to develop advanced vaccines that address viral infections linked to premature aging and shortened lifespan. The platform improves RNA cargo's effectiveness, promoting significant protein production for enhanced protection.

$ 100,000
raised
View Project

Discovering Novel Autophagy Activators

IP-NFT

Autophagy - the mechanism to recycle cellular components - becomes dysregulated with age and is associated with numerous diseases. The Korolchuk lab, based at Newcastle University, will screen a compound library to identify novel autophagy-activating compounds with the aim of restoring autophagy function to aged cells.

$ 285,000
raised
View Project

Are you working on the next longevity science breakthrough?

Apply for funding

About VitaDAO

Who can apply?
What types of projects do you fund?
What is the application structure?
Who owns IP from funded projects?
What project stages do you fund?